Caterpillar bids for Australia’s RPMGlobal- AFR
Investing.com -- Anbio Biotechnology, a global diagnostic company, announced the pricing of its initial public offering (IPO) at $5.00 per Class A Ordinary Share. However, the shares opened at a higher price of $5.26 per share on Wednesday, a 5% increase. Anbio is releasing 1,600,000 Class A ordinary shares in this offering. Anbio is currently trading on the Nasdaq stock exchange under the ticker "NNNN".
Anbio anticipates receiving total gross proceeds of $8 million from this offering, before subtracting underwriting discounts and other associated expenses. AC Sunshine Securities LLC is serving as the underwriter for this offering.
Anbio Biotechnology is a company committed to advancing medical technology and providing in vitro diagnostics (IVD) products. The company offers a diverse portfolio of mature diagnostic assays and five key platforms for biomarker detection. These platforms include Fluorescent Immunochromatographic Solution (FIA), Chemiluminescent Immunoassay Solution (ChLIA), Polymerase Chain Reaction Solution (PCR), Lateral Flow Assay Solution (LFIA), and Loop-Mediated Isothermal Amplification Solution (LAMP).
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.